Real-World Marijuana Use Is Associated With Altered Nocturnal Cardiac Autonomic Function, Reduced Sleep Quality, and Declining Consumption During Wearable Monitoring
- 1WHOOP Inc.
Abstract
BackgroundMarijuana is among the most widely used controlled substances, with use rising as risk perception declines. Despite growing acceptance, concerns remain regarding its effects on cardiovascular and autonomic physiology, sleep, and risk of cannabis use disorder. Although laboratory and epidemiological studies have characterized these associations, objective evidence from real-world settings is limited.
MethodsWe studied cardiac autonomic function, sleep, and marijuana use patterns in 16,965 consumer-wearable device users, contributing a total of 5,226,739 person-days of data with or without self-reported use of marijuana. Linear mixed models related day-level use to nocturnal cardiac autonomic function (resting heart rate [RHR], heart rate variability [HRV]) and sleep (duration, fragmentation, architecture) at the within- and between-person levels. Binomial mixed models were used to estimate use probability across 72 weeks of marijuana tracking.
ResultsMembers reported marijuana use on a median of 25.1% of logged days (IQR, 7.1-62.6%). Within individuals, use was associated with lower RHR (-0.12bpm; 99.5% CI: [-0.14, -0.10]) and lower HRV (-0.47ms [-0.53, -0.42]). Sleep was longer (+7.60min [7.37, 7.83]) but more fragmented, with more disturbances (+0.47 [0.45, 0.48]), greater wake time (+1.79min [1.70, 1.89]), and altered wearable-estimated sleep architecture. Daily use probability declined over 72 weeks (-11.1% [-11.5, -10.8]).
ConclusionsMarijuana use was associated with altered nocturnal cardiac autonomic physiology and longer but more disrupted sleep. Marijuana use declined after commencing tracking, raising the possibility that longitudinal self-monitoring may influence use. These findings extend laboratory evidence on marijuana use to real-world settings and demonstrate the potential of consumer wearables for studying substance use and its physiological correlates at scale.
HighlightsO_LIMarijuana-use nights were associated with lower resting heart rate and heart rate variability. C_LIO_LISleep was prolonged but more fragmented with marijuana use. C_LIO_LIMarijuana use fell over 72 weeks of wearable tracking. C_LI
Related
- Identification of factors associated with failure to meet nocturnal penile tumescence and rigidity criteria based on RigiScan monitoring and machine learning algorithms: a cross-sectional study
- Monitoring nocturnal movement and sleep in Parkinson’s disease: a systematic review of movement sensors
- Longitudinal Trajectories of Autonomic Maturation in Preterm Infants Using Serial 24-Hour Heart Rate Variability Monitoring.
- Preserved cardiac vagal tone is associated with nocturnal glycaemic stability
- Multidimensional autonomic dynamics are associated with clinical improvement across psychiatric patients
BibTeX
@misc{curran2026realworld,
title = {{Real-World Marijuana Use Is Associated With Altered Nocturnal Cardiac Autonomic Function, Reduced Sleep Quality, and Declining Consumption During Wearable Monitoring}},
author = {D. Curran and W. von Hippel and F. Fielding and S. R. Jasinski and J. Leota and J. G. Cohen and K. E. Holmes and G. J. Grosicki and C. P. Cheung},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.15.26363138},
url = {https://www.medrxiv.org/content/10.64898/2026.09.15.26363138v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Real-World Marijuana Use Is Associated With Altered Nocturnal Cardiac Autonomic Function, Reduced Sleep Quality, and Declining Consumption During Wearable Monitoring
AU - D. Curran
AU - W. von Hippel
AU - F. Fielding
AU - S. R. Jasinski
AU - J. Leota
AU - J. G. Cohen
AU - K. E. Holmes
AU - G. J. Grosicki
AU - C. P. Cheung
PY - 2026
DA - 2026/09/15
PB - medRxiv
DO - 10.64898/2026.09.15.26363138
UR - https://www.medrxiv.org/content/10.64898/2026.09.15.26363138v1
AB - BackgroundMarijuana is among the most widely used controlled substances, with use rising as risk perception declines. Despite growing acceptance, concerns remain regarding its effects on cardiovascular and autonomic physiology, sleep, and risk of cannabis use disorder. Although laboratory and epidemiological studies have characterized these associations, objective evidence from real-world settings is limited. MethodsWe studied cardiac autonomic function, sleep, and marijuana use patterns in 16,965 consumer-wearable device users, contributing a total of 5,226,739 person-days of data with or without self-reported use of marijuana. Linear mixed models related day-level use to nocturnal cardiac autonomic function (resting heart rate [RHR], heart rate variability [HRV]) and sleep (duration, fragmentation, architecture) at the within- and between-person levels. Binomial mixed models were used to estimate use probability across 72 weeks of marijuana tracking. ResultsMembers reported marijuana use on a median of 25.1% of logged days (IQR, 7.1-62.6%). Within individuals, use was associated with lower RHR (-0.12bpm; 99.5% CI: [-0.14, -0.10]) and lower HRV (-0.47ms [-0.53, -0.42]). Sleep was longer (+7.60min [7.37, 7.83]) but more fragmented, with more disturbances (+0.47 [0.45, 0.48]), greater wake time (+1.79min [1.70, 1.89]), and altered wearable-estimated sleep architecture. Daily use probability declined over 72 weeks (-11.1% [-11.5, -10.8]). ConclusionsMarijuana use was associated with altered nocturnal cardiac autonomic physiology and longer but more disrupted sleep. Marijuana use declined after commencing tracking, raising the possibility that longitudinal self-monitoring may influence use. These findings extend laboratory evidence on marijuana use to real-world settings and demonstrate the potential of consumer wearables for studying substance use and its physiological correlates at scale. HighlightsO_LIMarijuana-use nights were associated with lower resting heart rate and heart rate variability. C_LIO_LISleep was prolonged but more fragmented with marijuana use. C_LIO_LIMarijuana use fell over 72 weeks of wearable tracking. C_LI
ER -